Thomas R. Parr

Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections

IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections.

Xenogen Corp. provides real time in-vivo imaging services and genetic modification technologies. Its products and technologies include an imaging system, software, and biological materials. Its solutions are designed to improve discovery and pre-clinical research in multiple therapeutic areas. The company was founded by Pamela Reilly Contag and Christopher H. Contag in 1995 and is headquartered in Alameda, CA.

Targanta Therapeutics Corp. discovers and develops novel antibacterial pro drugs. The company was founded in 1997 and is headquartered in Parsippany, NJ.

MicroGenomics, Inc. develops technology to uncover molecular and genetic diversity in microorganisms that can not be cultured in the laboratory. The company is headquartered in Solana Beach, CA.

Targanta Therapeutics, Inc. develops antibiotic drugs and other related products. It focuses on developing and commercializing novel antibacterial agents to address unmet medical needs in the hospital market. The company also develops antibacterial pro-drugs for the treatment and prevention of bone infections. Targanta Therapeutics was founded in May 2007 and is located in St. Laurent, Canada

Adaptive Therapeutics, Inc. develops pharmaceutical products. It develops drugs for applications in anti-bacterial, fungal, viral, and cancer therapeutics. The company was founded in 2002 and is headquartered in San Diego, CA